FUNDAMENTALS · Fundamentals · US Healthcare

Vertex Pharmaceuticals (VRTX) Fundamentals 2026 — P/E 27.7x, Revenue Analysis | SniperIQ

Vertex Pharmaceuticals (VRTX) is a US-listed Healthcare company in Biotechnology with a market capitalization of

19.7B, trading at $471.74 on the NASDAQ. This SniperIQ fundamentals page covers Vertex Pharmaceuticals's valuation (P/E 27.7x, P/B 6.2x), profitability (net margin 35.4%), revenue (
2.1B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market Cap
19.7B
P/E (TTM)27.7x
Net Margin35.4%
Revenue (FY25)
2.1B

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is Vertex Pharmaceuticals's market cap?

Vertex Pharmaceuticals (VRTX) has a market capitalization of approximately

19.7B, trading at $471.74 on the NASDAQ. Market cap moves with the live share price.

What is Vertex Pharmaceuticals's P/E ratio?

Vertex Pharmaceuticals's trailing twelve-month P/E ratio is 27.7x, with a price-to-book (P/B) of 6.2x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Vertex Pharmaceuticals?

Vertex Pharmaceuticals runs a net profit margin of 35.4%, a gross margin of 86.3%, and an operating margin of 39.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Vertex Pharmaceuticals generate?

Vertex Pharmaceuticals reported revenue of

2.1B for fiscal year 2025, with net income of $4.0B and earnings per share (EPS) of 15.46. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Vertex Pharmaceuticals pay a dividend?

Vertex Pharmaceuticals does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is Vertex Pharmaceuticals financially healthy?

Vertex Pharmaceuticals carries a debt-to-equity ratio of 0.10x and a current ratio of 3.02x, with a market beta of 0.29. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Vertex Pharmaceuticals a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Vertex Pharmaceuticals (VRTX) the key facts are: market cap

19.7B, P/E 27.7x, revenue
2.1B, 52-week range 362.5-533.67. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track Vertex Pharmaceuticals's full fundamentals live

Get Vertex Pharmaceuticals's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.

Related: Macrogen (038290) fundamentals · SAMSUNG PHARM (001360) fundamentals · Sichuan Kelun-Biotech Biopharmaceutical (6990) fundamentals · Kyongbo Pharmaceutical (214390) fundamentals · All stock fundamentals · AI signal library
Research Hubs: Fundamentals library · Screeners · Institutional positioning · Super investors · Daily signals · Platform comparisons